Cancer Research 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 32, 1647-1650, August 1, 1972]
© 1972 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rathbone, M. P.
Right arrow Articles by Hall, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rathbone, M. P.
Right arrow Articles by Hall, R. H.

Metabolism and Biological Effects of N6-({Delta}2-Isopentenyl)-adenosine on a Cell Line Derived from Circulating Leukocytes of a Patient with Chronic Myelogenous Leukemia1

Michel P. Rathbone2 and Ross H. Hall

Department of Biochemistry, McMaster University, Hamilton, Ontario, Canada

N6-({Delta}2-Isopentenyl)adenosine (i6 Ado) at a concentration of 3 µM inhibits the growth of a line of cells derived from the circulating leukocytes of a patient with myelogenous leukemia, Roswell Park Memorial Institute line 6410. No alteration in the alkaline phosphatase activity of these cells is observed under these conditions.

i6 Ado is a component of 6410 cell tRNA but could not be detected as a nucleoside free in the cells or culture medium. The tRNA of cells cultured in the presence of i6 Ado contains a normal complement of {Delta}2-isopentenyl groups.

Line 6410 cells contain an enzyme activity that converts i6Ado to the corresponding base, which is much less toxic to these cells.

1 This work was supported by a grant from the National Cancer Institute of Canada and by Grant MT-2738 from the Medical Research Council of Canada.

2 Research Fellow of the National Cancer Institute of Canada.

Received 10/26/71. Accepted 4/18/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1972 by the American Association for Cancer Research.